A citation-based method for searching scientific literature

Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 61







List of co-cited articles
356 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res. Clin. Pract. 2016
25
12

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J. Clin. Endocrinol. Metab. 2014
60
5

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res. Clin. Pract. 2013
53
5


Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...].  2019
61
4

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona.  2020
7
42

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Robert R Henry, Poul Strange, Rong Zhou, Jeremy Pettus, Leon Shi, Sergey B Zhuplatov, Traci Mansfield, David Klein, Arie Katz. Diabetes Technol. Ther. 2018
20
15

Type 1 diabetes through the life span: a position statement of the American Diabetes Association.
Jane L Chiang, M Sue Kirkman, Lori M B Laffel, Anne L Peters. Diabetes Care 2014
379
4

SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Simeon I Taylor, Jenny E Blau, Kristina I Rother, Amber L Beitelshees. Lancet Diabetes Endocrinol 2019
13
23

Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
Gayatri Sarkar, May Alattar, Rebecca J Brown, Michael J Quon, David M Harlan, Kristina I Rother. Diabetes Care 2014
47
6

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
45
6

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
3
100

Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia.
Thomas H Meek, Mauricio D Dorfman, Miles E Matsen, Jonathan D Fischer, Alexis Cubelo, Monica R Kumar, Gerald J Taborsky, Gregory J Morton. Diabetes 2015
19
10

Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study.
Ram Weiss, Satish K Garg, Bruce W Bode, Timothy S Bailey, Andrew J Ahmann, Kenneth A Schultz, John B Welsh, John J Shin. Diabetes Technol. Ther. 2015
30
6

Outpatient glycemic control with a bionic pancreas in type 1 diabetes.
Steven J Russell, Firas H El-Khatib, Manasi Sinha, Kendra L Magyar, Katherine McKeon, Laura G Goergen, Courtney Balliro, Mallory A Hillard, David M Nathan, Edward R Damiano. N. Engl. J. Med. 2014
291
3

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno. N. Engl. J. Med. 2017
101
3

SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Halis Kaan Akturk, Amanda Rewers, Satish K Garg. Curr Opin Endocrinol Diabetes Obes 2018
4
50

Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
Frederik Staels, Carolien Moyson, Chantal Mathieu. Diabetes Obes Metab 2017
13
15


Targeting postprandial hyperglycemia.
Marc S Rendell, Lois Jovanovic. Metab. Clin. Exp. 2006
43
4

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder.  2010
126
3

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Brian Zambrowicz, Zhi-Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Melinda Smith, Dennis Ruff, Arthur Sands,[...]. Clin Ther 2013
50
4

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion.
Valentin Gorboulev, Annette Schürmann, Volker Vallon, Helmut Kipp, Alexander Jaschke, Dirk Klessen, Alexandra Friedrich, Stephan Scherneck, Timo Rieg, Robyn Cunard,[...]. Diabetes 2012
332
3

Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Nicole C Goodwin, Ross Mabon, Bryce A Harrison, Melanie K Shadoan, Zheng Y Almstead, Yiling Xie, Jason Healy, Lindsey M Buhring, Christopher M DaCosta, Jennifer Bardenhagen,[...]. J. Med. Chem. 2009
33
6



I. Glucose galactose malabsorption.
E M Wright. Am. J. Physiol. 1998
62
3

Diabetic ketoacidosis in pregnancy.
Jason A Parker, Deborah L Conway. Obstet. Gynecol. Clin. North Am. 2007
32
6


Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J Bailey, Cathrina Karup, Anna M Langkilde. Diabetes Obes Metab 2018
58
3


Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study.
G Riccardi, R Giacco, M Parillo, S Turco, A A Rivellese, M R Ventura, S Contadini, G Marra, M Monteduro, F Santeusanio,[...]. Diabet. Med. 1999
20
10


The effect of rosiglitazone on overweight subjects with type 1 diabetes.
Suzanne M Strowig, Philip Raskin. Diabetes Care 2005
38
5

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
104
3


Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
3

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad. Lancet Diabetes Endocrinol 2016
31
6





Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
69
3

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients.
Antonio Ceriello, Katherine Esposito, Ludovica Piconi, Michael A Ihnat, Jessica E Thorpe, Roberto Testa, Massimo Boemi, Dario Giugliano. Diabetes 2008
563
3

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.
Louis Monnier, Claude Colette, Anne Wojtusciszyn, Sylvie Dejager, Eric Renard, Nicolas Molinari, David R Owens. Diabetes Care 2017
75
3



Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters.
Lorena Alarcon-Casas Wright, Irl B Hirsch. Diabetes Technol. Ther. 2017
49
4


Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Bernard Zinman, Steven P Marso, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Martin Lange, Kirstine Brown-Frandsen, Alan Moses, Ann Marie Ocampo Francisco,[...]. Diabetologia 2018
52
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.